MiNK Therapeutics, Inc.
INKT
$11.90
$0.453.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.74% | -4.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.63% | 6.52% | |||
| Operating Income | -11.63% | -6.52% | |||
| Income Before Tax | -14.07% | -5.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.07% | -5.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.07% | -5.39% | |||
| EBIT | -11.63% | -6.52% | |||
| EBITDA | -11.78% | -6.70% | |||
| EPS Basic | -8.94% | -2.95% | |||
| Normalized Basic EPS | -8.96% | -2.94% | |||
| EPS Diluted | -8.94% | -2.95% | |||
| Normalized Diluted EPS | -8.96% | -2.94% | |||
| Average Basic Shares Outstanding | 4.70% | 2.38% | |||
| Average Diluted Shares Outstanding | 4.70% | 2.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||